Literature DB >> 16636457

Identification of AMP N1-oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells.

Noriko Hattori1, Hiroshi Nomoto, Satoshi Mishima, Shinsuke Inagaki, Masashi Goto, Magoichi Sako, Shoei Furukawa.   

Abstract

An extract of royal jelly (RJ) induced processes from cultured rat pheochromocytoma PC12 cells. Active components were isolated, and identified as adenosine monophosphate (AMP) and AMP N1-oxide. AMP N1-oxide was more than 20 times as active as AMP, judging from the minimal concentration to elicit activity. AMP N1-oxide was thought to be responsible for about half of the process-forming activity of whole RJ. Chemically-synthesized AMP N1-oxide was active similarly to the molecule purified from RJ, confirming AMP N1-oxide as the active entity. AMP N1-oxide also suppressed proliferation of PC12 cells and stimulated expression of neurofilament M, a specific protein of mature neurons, demonstrating the stimulatory activity of AMP N1-oxide to induce neuronal differentiation of PC12 cells. Pharmacological experiments suggested that AMP N1-oxide actions are mediated by adenyl cyclase-coupled adenosine receptors, including A2A. Thus AMP N1-oxide is a key molecule that characterizes RJ, and is not found in natural products other than RJ.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636457     DOI: 10.1271/bbb.70.897

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  9 in total

Review 1.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

2.  Royal jelly facilitates restoration of the cognitive ability in trimethyltin-intoxicated mice.

Authors:  Noriko Hattori; Shozo Ohta; Takashi Sakamoto; Satoshi Mishima; Shoei Furukawa
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-25       Impact factor: 2.629

3.  Antidepressant-like activity of 10-hydroxy-trans-2-decenoic Acid, a unique unsaturated Fatty Acid of royal jelly, in stress-inducible depression-like mouse model.

Authors:  Satoru Ito; Yuji Nitta; Hidefumi Fukumitsu; Hitomi Soumiya; Kumiko Ikeno; Tadashi Nakamura; Shoei Furukawa
Journal:  Evid Based Complement Alternat Med       Date:  2011-07-24       Impact factor: 2.629

4.  Anti-inflammatory effects of adenosine N1-oxide.

Authors:  Keizo Kohno; Emiko Ohashi; Osamu Sano; Hajime Kusano; Toshio Kunikata; Norie Arai; Toshiharu Hanaya; Toshio Kawata; Tomoyuki Nishimoto; Shigeharu Fukuda
Journal:  J Inflamm (Lond)       Date:  2015-01-20       Impact factor: 4.981

Review 5.  New Insights into the Biological and Pharmaceutical Properties of Royal Jelly.

Authors:  Saboor Ahmad; Maria Graça Campos; Filippo Fratini; Solomon Zewdu Altaye; Jianke Li
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

6.  AMP N(1)-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase.

Authors:  Noriko Hattori; Hiroshi Nomoto; Hidefumi Fukumitsu; Satoshi Mishima; Shoei Furukawa
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-29       Impact factor: 2.629

Review 7.  Royal Jelly-A Traditional and Natural Remedy for Postmenopausal Symptoms and Aging-Related Pathologies.

Authors:  Andreea Bălan; Marius Alexandru Moga; Lorena Dima; Sebastian Toma; Andrea Elena Neculau; Costin Vlad Anastasiu
Journal:  Molecules       Date:  2020-07-20       Impact factor: 4.411

8.  Search of Neuroprotective Polyphenols Using the "Overlay" Isolation Method.

Authors:  Hiroshi Sakagami; Haixia Shi; Kenjiro Bandow; Mineko Tomomura; Akito Tomomura; Misaki Horiuchi; Tomohiro Fujisawa; Takaaki Oizumi
Journal:  Molecules       Date:  2018-07-24       Impact factor: 4.411

Review 9.  Apitherapy for Parkinson's Disease: A Focus on the Effects of Propolis and Royal Jelly.

Authors:  Amira Mohammed Ali; Hiroshi Kunugi
Journal:  Oxid Med Cell Longev       Date:  2020-10-17       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.